Overview of systematic reviews of Qingkailing Injection.
10.19540/j.cnki.cjcmm.20210407.502
- Author:
Ke-Lu YANG
1
;
Yuan-Yuan LI
1
;
Jin XIE
2
;
Ya GAO
3
;
Ming LIU
3
;
Jin-Hui TIAN
4
Author Information
1. Evidence-based Nursing Center,School of Nursing,Lanzhou University Lanzhou 730000,China.
2. Dongfang Hospital,Beijing University of Chinese Medicine Beijing 100078,China.
3. Evidence-based Medicine Center,Lanzhou University Lanzhou 730000,China School of Basic Medical Sciences,Lanzhou University Lanzhou 730000,China.
4. Evidence-based Nursing Center,School of Nursing,Lanzhou University Lanzhou 730000,China Evidence-based Medicine Center,Lanzhou University Lanzhou 730000,China School of Basic Medical Sciences,Lanzhou University Lanzhou 730000,China Key Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province,Lanzhou University Lanzhou 730000,China.
- Publication Type:Journal Article
- Keywords:
AMSTAR 2;
Qingkailing Injection;
overview of systematic reviews
- MeSH:
Drugs, Chinese Herbal/adverse effects*;
Humans;
Injections;
Medicine, Chinese Traditional;
Systematic Reviews as Topic
- From:
China Journal of Chinese Materia Medica
2021;46(13):3446-3454
- CountryChina
- Language:Chinese
-
Abstract:
Qingkailing Injection is one of the most commonly used traditional Chinese medicine injections with significant clinical application for the treatment of multiple diseases. This study aims to analyze the systematic reviews( SRs) of Qingkailing Injection,in order to provide reference for the clinical application of Qingkailing Injection and the development of relevant clinical practice guidelines. We searched CNKI,CBM,Wanfang,VIP,Pub Med,Cochrane Library and EMbase to collect SRs from the time of database establishment to August 2020. The eligible SRs were included according to the inclusion and exclusion criteria. AMSTAR 2 was used to assess the methodological quality. The diseases,drugs in combinations and results were extracted and analyzed. A total of 24 SRs were selected,including 10 for the treatment of acute cerebrovascular diseases,9 for respiratory infections,2 for viral hepatitis,1 for chronic obstructive pulmonary disease,and two for the adverse effects of Qingkailing Injection. Only three entries of AMSTAR 2 item were fully reported by over 70%,and the rest were reported by less than 70%,with no report about item 2,3 and 10. Twenty-nine outcome indicators were correlated with the included SRs,of which three mostly frequent outcomes were effectiveness,adverse reaction,and neurological deficit scores,showing a good efficacy of Qingkailing Injection. The common severe adverse reaction was anaphylaxis,and mild adverse reactions were skin and mucous membrane reactions. The most frequently combined drug was antibiotics,mainly Penicillin and Penicillin+Pioneeromycin. The existing evidences showed that the methodological quality of SRs of Qingkailing Injection needed to be improved and Qingkailing Injection had an obvious efficacy. However,the selection of outcome indicators for clinical trials and SRs shall be standardized,and the reporting of basic information,such as drug combination,shall be strengthened to provide more powerful clinical services.
